KR20210126653A - Tno155 및 리보시클립을 포함하는 약제학적 조합물 - Google Patents

Tno155 및 리보시클립을 포함하는 약제학적 조합물 Download PDF

Info

Publication number
KR20210126653A
KR20210126653A KR1020217028654A KR20217028654A KR20210126653A KR 20210126653 A KR20210126653 A KR 20210126653A KR 1020217028654 A KR1020217028654 A KR 1020217028654A KR 20217028654 A KR20217028654 A KR 20217028654A KR 20210126653 A KR20210126653 A KR 20210126653A
Authority
KR
South Korea
Prior art keywords
day
amino
cancer
pharmaceutically acceptable
tno155
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217028654A
Other languages
English (en)
Korean (ko)
Inventor
잉-난 판 천
화이시앙 하오
천 리우
모바리드 모세니
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20210126653A publication Critical patent/KR20210126653A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217028654A 2019-02-12 2020-02-10 Tno155 및 리보시클립을 포함하는 약제학적 조합물 Ceased KR20210126653A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804708P 2019-02-12 2019-02-12
US62/804,708 2019-02-12
PCT/IB2020/051031 WO2020165734A1 (en) 2019-02-12 2020-02-10 Pharmaceutical combination comprising tno155 and ribociclib

Publications (1)

Publication Number Publication Date
KR20210126653A true KR20210126653A (ko) 2021-10-20

Family

ID=69724013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028654A Ceased KR20210126653A (ko) 2019-02-12 2020-02-10 Tno155 및 리보시클립을 포함하는 약제학적 조합물

Country Status (14)

Country Link
US (1) US12343344B2 (https=)
EP (1) EP3923941B1 (https=)
JP (1) JP7493521B2 (https=)
KR (1) KR20210126653A (https=)
CN (1) CN113382731A (https=)
AU (3) AU2020222296B2 (https=)
BR (1) BR112021015632A2 (https=)
CA (1) CA3127286A1 (https=)
CL (1) CL2021002099A1 (https=)
ES (1) ES3063733T3 (https=)
IL (1) IL284835B2 (https=)
MX (1) MX2021009563A (https=)
TW (1) TWI831916B (https=)
WO (1) WO2020165734A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240097396A (ko) 2022-12-20 2024-06-27 재단법인대구경북과학기술원 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112322A1 (en) 2018-09-29 2020-04-02 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
JP2022502385A (ja) 2018-09-29 2022-01-11 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物の製造方法
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
MX2021009562A (es) * 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
CN115916786B (zh) 2020-07-08 2025-10-17 诺华股份有限公司 用于抑制shp2活性的化合物和组合物的制造
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
IL308234A (en) * 2021-05-05 2024-01-01 Huyabio Int Llc Monotherapy with an SHP2 inhibitor and its uses
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
CN117177752A (zh) * 2021-05-05 2023-12-05 诺华股份有限公司 用于治疗mpnst的化合物和组合物
US20240293422A1 (en) * 2021-06-24 2024-09-05 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US20190343836A1 (en) * 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
CA3074690A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
AU2019403048B2 (en) 2018-12-17 2025-01-23 Lunella Biotech, Inc. Triple combination therapies for targeting mitochondria and killing cancer stem cells
CN113453690A (zh) 2018-12-17 2021-09-28 卢内拉生物技术有限公司 用于抗衰老的三联疗法
WO2020165732A1 (en) * 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
MX2021009562A (es) 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240097396A (ko) 2022-12-20 2024-06-27 재단법인대구경북과학기술원 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CA3127286A1 (en) 2020-08-20
AU2020222296B2 (en) 2023-04-06
CL2021002099A1 (es) 2022-04-18
MX2021009563A (es) 2021-09-08
IL284835B2 (en) 2025-08-01
AU2023203751A1 (en) 2023-07-13
IL284835A (en) 2021-08-31
JP2022519375A (ja) 2022-03-23
IL284835B1 (en) 2025-04-01
ES3063733T3 (en) 2026-04-20
EP3923941A1 (en) 2021-12-22
US20220160707A1 (en) 2022-05-26
WO2020165734A1 (en) 2020-08-20
AU2025203816A1 (en) 2025-06-12
BR112021015632A2 (pt) 2021-10-05
US12343344B2 (en) 2025-07-01
AU2020222296A1 (en) 2021-08-05
CN113382731A (zh) 2021-09-10
JP7493521B2 (ja) 2024-05-31
EP3923941B1 (en) 2025-12-03
TWI831916B (zh) 2024-02-11
TW202045171A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
KR20210126653A (ko) Tno155 및 리보시클립을 포함하는 약제학적 조합물
JP7572958B2 (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
KR20220148847A (ko) 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물
US20230093147A1 (en) Methods and compositions relating to improved combination therapies
JP7490635B2 (ja) Ｅｇｆｒ変異がんの処置
TW201032796A (en) Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
Konar et al. Synthesis and clinical development of palbociclib: An overview
WO2023009701A2 (en) Therapeutic regimens of a degrader of brd9
US20240180923A1 (en) Methods of treating disorders with ulk inhibitors
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601